ResearcherSaint Joseph UniversityNo recent work listed
Marwan G. Ghosn
Matched on ORCID iD 0000-0003-1627-384X; OpenAlex author ID A5032858753. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 6
2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: 3 papers · 2017: 1 paper
Papers 6
- Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospe… Co-author DOI 10.1016/j.clinre.2016.11.012↗
- Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. Co-author DOI 10.3748/wjg.v22.i46.10124↗
- Is metastatic pancreatic cancer an untargetable malignancy? Last author DOI 10.4251/wjgo.v8.i3.297↗
- Road map for pain management in pancreatic cancer: A review. Last author DOI 10.4251/wjgo.v8.i8.599↗
- Optimum chemotherapy in the management of metastatic pancreatic cancer. Co-author DOI 10.3748/wjg.v20.i9.2352↗
- Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer. Co-author DOI 10.1007/s12032-012-0197-9↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hampig Raphaël Kourié · 3 shared papers, 2016 · strength 0.22
- Joseph Gergi Kattan · 3 shared papers, 2012–2017 · strength 0.20
- Paper Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox … DOI 10.1016/j.clinre.2016.11.012↗
- Paper Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. DOI 10.3748/wjg.v22.i46.10124↗
- Paper Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer. DOI 10.1007/s12032-012-0197-9↗
- Tarek Assi · 2 shared papers, 2016–2017 · strength 0.16
- Elie Rassy · 2 shared papers, 2016–2017 · strength 0.16
- Marie José Lahoud · 1 shared paper, 2016 · strength 0.08
- Fadi Sami Farhat · 1 shared paper, 2012 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.